Bafna Pharmaceuticals Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 137.5 as of 06 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 16.5 on March 2021 to 26.6 on March 2025 . This represents a CAGR of 10.02% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 176.64 crore on March 2021 to ₹ 464.72 crore on March 2025 . This represents a CAGR of 21.34% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sakar Healthcare Ltd for the Dec '25 is ₹ 70.85 crore as compare to the Sep '25 revenue of ₹ 58.78 crore. This represent the growth of 20.53% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sakar Healthcare Ltd for the Dec '25 is ₹ 19.1 crore as compare to the Sep '25 ebitda of ₹ 12.57 crore. This represent the growth of 51.95% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 10.25 crore over 7 quarters. This represents a CAGR of 128.70% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Sakar Healthcare Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 325 Cr while Market cap of Sakar Healthcare Ltd is 1,330 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd?

As of May 6, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹137.5. On the other hand, Sakar Healthcare Ltd stock price is INR ₹598.0.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.